Yang K, Han L, Wu S, Qu X, Li Q, Zhao C, et al
Food and Drug Administration Primary regulatory Mar 31, 2026 accessed Jun 30, 2026 FDA warning letter discussing peptide products marketed online and the limits of research-use-only positioning
Mar Drugs 21(3) Napirkowska-Baran K et al (2025) Immunomodulatory effects of selected non-nutritive bioactive compounds and their role in optimal nutrition
Of all the genetic variations identified to date, MS stands alone as a degenerative CNS disorder with no mutation that causes MS
Summary: Cagrilintide and retatrutide are investigational injectable medicines being studied for obesity and type 2 diabetes in men, targeting multiple hormonal pathways to reduce appetite, improve blood glucose control, and increase energy expenditure, but neither is currently licensed in the UK
Incorporating drugs with different mechanisms and personalized medicine may improve the efficacy to better benefit patients with NAFL/NASH